Ditchcarbon
  • Customers
  1. Organizations
  2. Alkermes
Public Profile
Pharmaceutical Preparation Manufacturing
IE
updated 9 days ago

Alkermes

Company website

Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.

DitchCarbon Score

How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

33

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Alkermes's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Let us know if this data was useful to you

Alkermes's reported carbon emissions

In 2023, Alkermes reported total greenhouse gas emissions of approximately 15,753,000 kg CO2e for Scope 1 and about 16,726,000 kg CO2e for Scope 2, resulting in a combined total of around 32,480,000 kg CO2e. This marks a slight decrease from 2022, where emissions were approximately 16,997,000 kg CO2e for Scope 1 and 16,813,000 kg CO2e for Scope 2, leading to a total of about 33,810,000 kg CO2e. Alkermes has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from their operations. The company has not set specific reduction targets under the Science Based Targets initiative (SBTi) or other formal climate pledges, which suggests a need for further commitment in this area. The emissions data reflects a commitment to transparency, with detailed reporting on emissions per employee, floor area, and revenue. For instance, the emissions per employee stand at about 250 kg CO2e, while emissions per square metre of floor area are approximately 50 kg CO2e. Overall, while Alkermes has made strides in emissions reporting, the absence of reduction targets highlights an opportunity for enhanced climate action and commitment to sustainability.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201520162017201820192020202120222023
Scope 1
13,960,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
17,785,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Alkermes's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Alkermes is in IE, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Alkermes is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Abbvie

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Sumitomo Pharma America, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Bayer Pharma AG

DE
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Genentech

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Indivior

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Coherus BioSciences, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy